Reuniting With the Affable Mr. Greg Halpern, 19 Years Later…
A Potential Christmas Present Arrives in our lap Early, From the Inventor of Crowdfunding and Winner of Incubator of The Year in...
News and Charts on Four Small Cap Telehealth and Remote Health Monitoring Plays.
After Losing $33 Billion in Value, Teladoc Health Snags an Upgrade.
With chances building...
Report: VYRE Network (CAPV).
Update Report: Our First Internet Play in Ages, and It’s a Doozy.
Reporting from the Great City...
Dalrada (DFCO). Our 11th and Latest Ten Bagger.
We've actually had many more than 11 ten-baggers, as we report on companies which aren't clients. This is our 11th client we...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
Revive Therapeutics Updates, on Phase III Clinical Trial!
Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.."
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.